Skip to main content
. Author manuscript; available in PMC: 2019 Jun 8.
Published in final edited form as: Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 2;84(Pt A):11–17. doi: 10.1016/j.pnpbp.2018.01.015

Table 3.

Factors associated with telomere length (T/S ratio) by cocaine use status, robust regression analyses*

Characteristic Univariate model
Regression
coefficient (95%CI) p-value
Initial multivariate model
Regression
coefficient (95%CI) p-value
Final multivariate model
Regression
coefficient (95%CI) p-value
Never cocaine use (N=22)
Daily alcohol use −0.0510(−0.4024, 0.0305)
0.77
−0.0548(−0.4210, 0.3114)
0.77
Low 2013 risk 0.0223(−0.2287, 0.2734)
0.86
0.0586(−0.2111, 0.3283)
0.67
NNRTI use 0.1759(−0.1020, 0.4538)
0.21
0.1983(−0.1029, 0.4995)
0.20
Chronic cocaine use (N=125)
Daily alcohol use −0.1118(−0.1801,−0.0435)
0.001
−0.1174(−0.1819,−0.0529)
0.0004
−0.1174(−0.1819,−0.0529)
0.0004
Low 2013 risk 0.0884( 0.0187, 0.1581)
0.01
0.0917(0.0270, 0.1563)
0.005
0.0917(0.0270, 0.1563)
0.005
NNRTI use 0.1007( 0.0103, 0.1910)
0.029
0.0865(0.0032,0.1699)
0.04
0.0865(0.0032,0.1699)
0.04
*

low 2013 risk, cardiovascular risk defined by the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk≤7.5% (Goff et al., 2014),

NNRTI, non-nucleoside reverse transcriptase inhibitor.